Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

June

1

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional...

12

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record...

6

Exagen Announces Campaign for Lupus Awareness Month

CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

1

Exagen Announces Five-Week Campaign for Lupus Awareness Month

Weekly themes to focus on diagnosis, advocacy, community, research, and motivation SAN DIEGO, May 01,...

27

Exagen Inc. Expands Coverage with Inland Empire Health Plan

Partnership to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus SAN...

13

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

Latest clinical utility study published in Lupus & Science Medicine SAN DIEGO, July 13, 2021 (GLOBE...

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis,...

3

Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

Joint effort with the Lupus Foundation of America and LupusChick SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE)...

16

Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results

Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes, and Adopters SAN DIEGO, March 16, 2021 (GLOBE...

16

Exagen and GSK Partner for Fourth Straight Year

Continued collaboration drives greater awareness of challenges facing lupus diagnosis and management SAN DIEGO, Nov....

10

Exagen Inc. Reports Third Quarter 2020 Results

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing...

12

New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors

Findings support the clinical need for an improved SLE diagnostic test SAN DIEGO, Oct. 12,...